Literature DB >> 10618685

The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

I M Svane1, M Boesen, A M Engel.   

Abstract

The idea of immunological surveillance against cancer has existed for nearly 100 years but as no conclusive evidence has yet been published the importance of the cellular immune defense in the detection and removal of incipient or existing tumors is still a hotly debated subject. However, in order to select a relevant immunotherapeutic strategy in the treatment of cancer, a fundamental understanding of the basic immunologic conditions under which a tumor develops and exists is a prerequisite. Therefore, a murine model was set up that we hoped would enable us to confirm or reject the theory of immunological surveillance. A large panel of methylcholanthrene induced tumors was established in T-cell immunodeficient nude mice and congenic normal mice to study the influence of the immune system on developing tumors. As nude mice developed tumors fastest and with the highest incidence, we concluded that in this model the immune system constituted a 'tumor-suppressive factor' delaying and sometimes abrogating tumor growth, i.e. performing immune surveillance. Immunogenicity of the tumors was assessed by transplantation back to normal histocompatible mice. Tumors originating from the immunodeficient nude mice turned out to be far more immunogenic than tumors from normal mice, resulting in a high rejection rate. CD8+ cytotoxic T cells were found to be indispensable for this rejection, leading to the conclusion that the cytotoxic T cells perform immune selection in normal mice, eliminating immunogenic tumor cell variants in the incipient tumor. In this review, we discuss the difficulties facing immunotherapy when conclusions are drawn from the presented observations and hypotheses.

Entities:  

Mesh:

Year:  1999        PMID: 10618685     DOI: 10.1007/bf02785868

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  128 in total

Review 1.  A new look at tumour immunology.

Authors:  W Bodmer
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

Review 2.  The host-tumor immune conflict: from immunosuppression to resistance and destruction.

Authors:  S Chouaib; C Asselin-Paturel; F Mami-Chouaib; A Caignard; J Y Blay
Journal:  Immunol Today       Date:  1997-10

3.  Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.

Authors:  J R Yannelli; C Hyatt; S McConnell; K Hines; L Jacknin; L Parker; M Sanders; S A Rosenberg
Journal:  Int J Cancer       Date:  1996-02-08       Impact factor: 7.396

4.  Interferon-gamma-induced MHC class I expression and defects in Jak/Stat signalling in methylcholanthrene-induced sarcomas.

Authors:  I M Svane; A M Engel; M Nielsen; O Werdelin
Journal:  Scand J Immunol       Date:  1997-10       Impact factor: 3.487

5.  Expression of beta 2-microglobulin by human benign and malignant mesenchymal and neurogenic tumours.

Authors:  B L Petersen; O Braendstrup
Journal:  Int J Exp Pathol       Date:  1993-08       Impact factor: 1.925

Review 6.  New tumor antigens recognized by T cells.

Authors:  B Van den Eynde; V G Brichard
Journal:  Curr Opin Immunol       Date:  1995-10       Impact factor: 7.486

Review 7.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

8.  Neoplasms in the acquired immune deficiency syndrome: the multidisciplinary approach to treatment.

Authors:  J E Groopman
Journal:  Semin Oncol       Date:  1987-06       Impact factor: 4.929

9.  Histocompatibility antigens on murine tumors.

Authors:  R S Goodenow; J M Vogel; R L Linsk
Journal:  Science       Date:  1985-11-15       Impact factor: 47.728

10.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  10 in total

1.  Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Authors:  Conrad R Cruz; Ulrike Gerdemann; Ann M Leen; Jessica A Shafer; Stephanie Ku; Benjamin Tzou; Terzah M Horton; Andrea Sheehan; Amanda Copeland; Anas Younes; Cliona M Rooney; Helen E Heslop; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

2.  Effect of beta blocker combined with COX-2 inhibitor on colonic anastomosis in rats.

Authors:  Barak Benjamin; Ofir Hazut; Lee Shaashua; Marganit Benish; Niv Zmora; Iris Barshack; Aviad Hoffman; Shamgar Ben-Eliyahu; Oded Zmora
Journal:  Int J Colorectal Dis       Date:  2010-06-16       Impact factor: 2.571

3.  Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis.

Authors:  B Fingleton; T Vargo-Gogola; H C Crawford; L M Matrisian
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

4.  Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity.

Authors:  H Komita; X Zhao; A K Katakam; P Kumar; M Kawabe; H Okada; J M Braughler; W J Storkus
Journal:  Cancer Gene Ther       Date:  2009-05-15       Impact factor: 5.987

5.  Dithiocarbamates and viral IL-10 collaborate in the immortalization and evasion of immune response in EBV-infected human B lymphocytes.

Authors:  Richard D Irons; Anh Tuan Le
Journal:  Chem Biol Interact       Date:  2007-11-22       Impact factor: 5.192

Review 6.  An immune reaction may be necessary for cancer development.

Authors:  Richmond T Prehn
Journal:  Theor Biol Med Model       Date:  2006-02-03       Impact factor: 2.432

7.  CD103 expression is required for destruction of pancreatic islet allografts by CD8(+) T cells.

Authors:  Ye Feng; Donghua Wang; Rongwen Yuan; Christina M Parker; Donna L Farber; Gregg A Hadley
Journal:  J Exp Med       Date:  2002-10-07       Impact factor: 14.307

Review 8.  Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse.

Authors:  Pablo A González; Leandro J Carreño; Pablo F Céspedes; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Clin Dev Immunol       Date:  2013-03-07

9.  Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis.

Authors:  Yiwen Li; Mei-Nai Wang; Hongli Li; Karen D King; Rajiv Bassi; Haijun Sun; Angel Santiago; Andrea T Hooper; Peter Bohlen; Daniel J Hicklin
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

10.  Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccination.

Authors:  Yanqin Ren; Na Wang; Weiguo Hu; Xiaoyan Zhang; Jianqing Xu; Yanmin Wan
Journal:  Sci Rep       Date:  2015-12-15       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.